Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
miR-100 as predictor of response to letrozole in luminal HER2-negative breast cancer
2020-004057-71Phase 2Completed
- Sponsor
- Fondazione del Piemonte per l'Oncologia
- Start
- May 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of letrozole in breast cancer, sponsored by Fondazione del Piemonte per l'Oncologia. Primary endpoint: Complete proliferative response based on Ki67. Started May 2021; status: completed.
02
Drugs
letrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2020-004057-71.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004057-71.